Specify a stock or a cryptocurrency in the search bar to get a summary
RenovoRx Inc
RNXTRenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. Address: 4546 El Camino Real, Los Altos, CA, United States, 94022
Analytics
WallStreet Target Price
5.25 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures RNXT
Dividend Analytics RNXT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RNXT
Stock Valuation RNXT
Financials RNXT
Results | 2019 | Dynamics |